Search

Intrapleural tissue plasminogen activator and deoxyribonuclease administered concurrently and once daily for complex parapneumonic pleural effusion and empyema

메타 데이터

바이오화학분류
    • 바이오정밀화학
      1. 기타
논문

Intrapleural tissue plasminogen activator and deoxyribonuclease administered concurrently and once daily for complex parapneumonic pleural effusion and empyema

학술지

Internal medicine journal

저자명

Smith, Dugal; Shaw, Hannah; Ryder, Timothy

초록

<P><B>Abstract</B></P><P><B>Background</B></P><P>Pleural infection is life&#8208;threatening and increasingly prevalent. In addition to usual care, twice&#8208;daily, separate administration of tissue plasminogen activator and deoxyribonuclease (tPA&#8208;DNase) reduces radiological pleural opacity with lower surgical referral rates.</P><P><B>Aims</B></P><P>This retrospective cohort study examines the use of once&#8208;daily, concurrent administration of tPA&#8208;DNase for complex parapneumonic pleural effusion and empyema.</P><P><B>Methods</B></P><P>Patients with pleural infection who received intrapleural tPA&#8208;DNase between October 2014 and July 2020 at Logan Hospital, where it is given concurrently and once&#8208;daily as salvage therapy, were retrospectively identified. Radiographic opacification, inflammatory markers, clinical response and complications were examined.</P><P><B>Results</B></P><P>Thirty&#8208;one patients were identified. Mean age was 48.8 years (standard deviation [SD], 17.2). Median tPA&#8208;DNase administration was 3 (interquartile range [IQR], 2&ndash;3). Chest x&#8208;ray pleural opacity decreased significantly (<I>P</I> = 0.047) from a median of 39.6% (IQR, 28.8&ndash;65.7%) to 9.7% (IQR, 2.5&ndash;23.2%), a median relative reduction of 75.5% (IQR, 47.7&ndash;93.9%). White cell count and C&#8208;reactive protein improved significantly (<I>P</I> = 0.002 and <I>P</I> = 0.032, respectively) from a median of 16.3 &times; 10<SUP>9</SUP>/L (IQR, 11.8&ndash;20.6 &times; 10<SUP>9</SUP>/L) to 9.9 &times; 10<SUP>9</SUP>/L (IQR, 8.0&ndash;12.3 &times; 10<SUP>9</SUP>/L) and 311.0 mg/L (IQR, 218.8&ndash;374.0 mg/L) to 69.0 mg/L (IQR, 36.0&ndash;118.0 mg/L), respectively. No patients experienced significant bleeding or died. Five patients (16.1%) were referred for surgery.</P><P><B>Conclusion</B></P><P>This is pilot evidence that a practical regimen of concurrent, once&#8208;daily intrapleural tPA&#8208;DNase improved pleural opacification and inflammatory markers without bleeding or mortality. The surgical referral rate was higher than in studies assessing twice&#8208;daily administration, though the validity of this outcome as a measure of treatment success is limited, and further studies are needed to assess the optimal dose and frequency of intrapleural therapy and indications for surgical referral.</P>

발행연도

2023

발행기관

John WileySons Australia, Ltd

ISSN

1444-0903

ISSN

1445-5994

53

12

페이지

pp.2313-2318

주제어

empyema; pleural; tissue plasminogen activator; pleural effusion; pleural space infection; intercostal catheter

0건의 논문이 있습니다.

0건의 특허가 있습니다.

0건의 무역이 있습니다.

1건의 후보군 물질이 있습니다.

1 2023-12-11

논문; 2023-12-01

Export

About

Search

Trend